Form 8-K - Current report:
SEC Accession No. 0000950170-24-125359
Filing Date
2024-11-12
Accepted
2024-11-12 16:07:59
Documents
12
Period of Report
2024-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K artv-20241112.htm   iXBRL 8-K 48193
2 EX-99.1 artv-ex99_1.htm EX-99.1 173372
  Complete submission text file 0000950170-24-125359.txt   357732

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT artv-20241112.xsd EX-101.SCH 32093
14 EXTRACTED XBRL INSTANCE DOCUMENT artv-20241112_htm.xml XML 4896
Mailing Address 5505 MOREHOUSE DRIVE SAN DIEGO CA 92121
Business Address 5505 MOREHOUSE DRIVE SAN DIEGO CA 92121 (858) 267-4467
Artiva Biotherapeutics, Inc. (Filer) CIK: 0001817241 (see all company filings)

EIN.: 863614316 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42179 | Film No.: 241448085
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)